{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":20,"n_cols":5,"rows_kept":20,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[13,2,13,3],[14,2,14,3],[17,2,17,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910416107603321"]
[null,null,"Titolo",null,"Pediatric Pharmacotherapy / / edited by Wieland Kiess, Matthias Schwab, Johannes van den Anker"]
[null,null,"Pubbl/distr/stampa",null,"Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020"]
[null,null,"ISBN",null,"3-030-50494-8"]
[null,null,"Edizione",null,"[1st ed. 2020.]"]
[null,null,"Descrizione fisica",null,"1 online resource (VIII, 538 p. 1 illus.)"]
[null,null,"Collana",null,"Handbook of Experimental Pharmacology, , 1865-0325 ; ; 261"]
[null,null,"Disciplina",null,"615.1083"]
[null,null,"Soggetti",null,"Pharmacology"]
[{"$nulls":4},"Pediatrics"]
[{"$nulls":4},"Quimioteràpia"]
[{"$nulls":4},"Pediatria"]
[{"$nulls":4},"Llibres electrònics"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references."]
[null,null,"Nota di contenuto",null,"Anti-epileptic drugs in pediatrics -- Current and new therapies for Duchenne Muscular Dystrophy -- Lysosomal diseases -- Mitochondriopathies -- Endocrinology thyroid, pituitary, growth stimulant, growth reduction -- Bone disease – bisphosphonates -- Diabetes type 1 and 3 (insulin; sulfonylurea; others) -- Diabetes type 2 (metformin etc.) -- Dermatology – part 1 urticaria, atopic dermatitis -- Dermatology part 2, ichtyosis, psoriasis -- Cardiovascular part 1- catcholamines, inotropic -- Cardiovascular part 2 – antiarhythmica, anti hypertensives -- Nephrology – dialysis -- How to use drugs in obese children and adolescents -- Haematology – CSFs, erythropoietin -- Antiretroviral/HIV -- Clinical pharmacology and pharmacometrics to better understand physiological changes during pregnancy and neonatal life -- Antihelminth treatment -- Inflammatory bowel disease -- Constipation; laxatives -- Psychiatric diseases in children and adolescents -- Oncology – cell reducing agents part 1, part 2, part 3 -- Immunosuppressants – organ transplantation -- Bone marrow/stem cell transplantation -- Narcotic sparing approaches and the shift towards paracetamol in neonatal intensive care -- Disorders of puberty: pharmacotherapeutic strategies for management."]
[null,null,null,"Sommario/riassunto","This volume provides readers with the most updated scientific information on the efficacy and safety of medicines for children and "]
[{"$nulls":4},"adolescents. The book enriches the understanding of pediatric pharmacotherapy for health professionals, regulatory agencies, pharmaceutical companies and learned societies. It contains important information on the pharmacodynamics and pharmacokinetics of drugs. It summarizes the latest investigations on the effects of pharmacological treatments in relation to and dependent on age, gender, fat mass and disease status. Therefore and importantly, this volume reviews the latest data on how pharmacotherapy has to be adjusted and personalized in regards to stages of development and during the pediatric lifespan from neonate through adolescence. In addition, the topic of rare diseases and special challenges for pharmacotherapy will be included and will provide readers with the necessary knowledge to handle complex diseases and treatment strategies especially in relation to pharmacotherapy of rare and orphan diseases."]